How is ILNS involved with CHF5074 mentioned in the filing since it looks like Dr. Chain has another company CereSpir that is in negotiations with Chiesi.
"CereSpir Incorporated and Chiesi Farmaceutici S.p.A. have signed a letter of intent and are negotiating a licensing agreement, whereby CereSpir will acquire the exclusive global development and commercialization rights to CHF 5074, a novel, first-in-class small molecule microglia modulator that was discovered and developed by Chiesi researchers."
The privately held company was founded by Daniel Chain, PhD, to focus exclusively on completing the clinical development of CHF 5074, which was created and developed by Chiesi Farmaceutici SpA of Parma, Italy. CHF 5074 is a small molecule with a unique microglial modulating activity that has demonstrated its potential to slow disease in patients with Mild Cognitive Impairment (MCI), the earliest stage of Alzheimer’s disease. On July 26, 2013, Chiesi Farmaceutici and CereSpir announced they had signed a Letter of Intent to transfer exclusive global development and commercialization rights to CHF 5074 to CereSpir. The License Agreement is expect to be completed imminently.
Dr. Chain is a seasoned, accomplished and knowledgeable entrepreneur, inventor and CEO who has spearheaded the development of several innovative therapeutic approaches in his unrelenting pursuit of a world without Alzheimer’s disease.